dilated cardiomyopathy

TOKYO, Japan, June 2026 Heartseed Inc. announced the successful treatment of the first patient in its Phase I/II EMERALD...

WALTHAM, Mass., April 28, 2026 Affinia Therapeutics has announced new progress for AFTX-201, its lead investigational gene therapy for...

Waltham, Massachusetts, USA, April 6, 2026 Health Canada Approval Marks Key Clinical Milestone In a significant development for cardiovascular...